Oribiotech deal validates AdAlta manufacturing strategy
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The CEO highlighted that this collaboration signals confidence in the automation of cell therapy manufacturing, which is crucial for commercial success. AdAlta aims to prioritize IRO® compatibility for future products, enhancing its appeal to potential pharmaceutical partners.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- BZDS1901 special access scheme launch in China
- EW-001 IIT study overall survival update
- 2 year survival milestone for EW-001 patient
- Oktopi AI collaboration for research efficiency
- Second BZDS1901 milestone paid
Later from AdAlta
- US FDA grants EW-001 pre-IND meeting
- China Representative Office opens
- EW-001 JDC milestone approvals
- RDTI receipt, Advanced Overseas Finding
- Quarterly Appendix 4C and Activities Report
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta